8-K: INVO Bioscience Reports Record 481% Revenue Growth in Second Quarter 2024

INVO Bioscience announced a 481% year-over-year revenue increase and a $1.1 million improvement in adjusted EBITDA for the second quarter of 2024.

Summary

• INVO Bioscience reported a significant increase in revenue for the second quarter of 2024, reaching $1,836,597, a 481% increase compared to the same period last year.
• Clinic revenue saw a substantial rise of 611%, totaling $1,807,921, primarily from the company's INVO Center in Atlanta and its fertility clinic in Middleton, Wisconsin.
• Total revenue from all clinics, including those accounted for under the equity method, was $2,141,229, a 201% increase year-over-year.
• The company's total operating expenses increased to $3.7 million, primarily due to a one-time non-cash expense of $1.0 million and a $0.2 million increase in amortization costs.
• The net loss remained at $(2.2) million, consistent with the previous year.
• Adjusted EBITDA improved to $(0.5) million, a $1.1 million improvement compared to $(1.6) million in the prior year.
• The company is aiming to reach breakeven with current operations and plans to resume acquisitions and new INVO Center activities in 2025.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with strong revenue growth and improved EBITDA, but the ongoing net loss and merger delays temper the overall sentiment. The company is showing progress but still faces challenges.

Positives

• The company experienced a substantial 481% increase in revenue year-over-year.
• Clinic revenue saw a significant 611% increase, indicating strong performance in the company's core business.
• Adjusted EBITDA improved by $1.1 million, showing progress towards profitability.
• The company's fertility centers are experiencing sequential revenue growth and are collectively profitable.
• The company plans to resume acquisitions and new INVO Center activities in 2025, indicating a growth-oriented strategy.

Negatives

• Total operating expenses increased by $1.3 million, primarily due to a one-time non-cash expense and increased amortization costs.
• The company reported a net loss of $(2.2) million, consistent with the previous year.
• The proposed merger with NAYA Biosciences has been delayed and is still under discussion for a further extension.

Risks

• The company's operating expenses increased significantly, impacting profitability.
• The net loss remains substantial, indicating ongoing financial challenges.
• The proposed merger with NAYA Biosciences is facing delays, which could affect the company's strategic plans.
• The company is reliant on the success of its fertility centers and the adoption of its INVOcell technology.

Future Outlook

The company aims to reach breakeven with current operations and plans to resume acquisitions and new INVO Center activities in 2025 to accelerate its path to profitability.

Management Comments

• The growing, positive impact of our acquisition strategy remains in full swing as we report record second quarter revenue up 481% year-over-year and 17% sequentially with a $1.1 million improvement in adjusted EBITDA, commented Steve Shum, CEO of INVO.
• Our fertility centers in Middleton, Atlanta, and Birmingham are all experiencing sequential revenue growth and are collectively profitable.
• This growth and clinic-level profit, coupled with our careful management of overall corporate expenses, positions us to achieve our stated goal of reaching breakeven with our current operations.
• To accelerate our path to profitability, we also expect to resume both our acquisition and new INVO Center activities in 2025.

Industry Context

The announcement reflects a positive trend in the fertility services market, where companies are focusing on expanding access to advanced treatments. INVO's strategy of acquiring and establishing fertility clinics aligns with this trend, and the company's INVOcell technology offers a unique approach to assisted reproductive technology.

Comparison to Industry Standards

• The 481% year-over-year revenue growth is significantly higher than the average growth rate for companies in the fertility services sector, which typically ranges from 10-30% annually.
• Companies like CooperSurgical and Vitrolife, which are established players in the IVF market, have shown consistent but less dramatic revenue growth in recent years.
• The $1.1 million improvement in adjusted EBITDA is a positive sign, but INVO's adjusted EBITDA of $(0.5) million is still below the breakeven point, while many established companies in the sector are profitable.
• The company's focus on the INVOcell technology and IVC procedure differentiates it from traditional IVF providers, potentially offering a more cost-effective solution, but it also carries the risk of lower adoption rates compared to established methods.

Stakeholder Impact

• Shareholders will likely view the strong revenue growth and improved EBITDA positively.
• Employees may benefit from the company's growth and expansion plans.
• Customers may have increased access to fertility treatments through the company's expanding network of clinics.
• Suppliers may see increased demand for their products and services.
• Creditors may view the improved financial performance as a positive sign.

Next Steps

• The company plans to resume acquisitions and new INVO Center activities in 2025.
• INVO and NAYA are in discussions to agree to a further extension of the merger agreement.

Key Dates

Keywords

INVO Bioscience, Fertility, IVF, INVOcell, Revenue Growth, EBITDA, Clinic Revenue, Merger, Healthcare Services, Assisted Reproductive Technology